Open AccessFatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival
Author(s) -
Kartika Widayati Taroeno-Hariadi,
Yasjudan Rastrama Putra,
Lina Choridah,
Irianiwati Widodo,
Mardiah Suci Hardianti,
Teguh Aryandono
Publication year - 2021
Publication title -
journal of breast cancer/journal of breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1
H-Index - 36
eISSN - 2092-9900
pISSN - 1738-6756
DOI - 10.4048/jbc.2021.24.e41
Subject(s) - medicine , breast cancer , metabolic syndrome , fatty liver , dyslipidemia , body mass index , overweight , oncology , endocrinology , gastroenterology , cancer , obesity , disease
Long-term estrogen inhibition may cause fatty liver disease (non-alcoholic fatty liver disease; NAFLD) among other adverse conditions such as osteoporosis, climacteric symptoms, thromboembolism, dyslipidemia, and metabolic syndrome. The prevalence of NAFLD among breast cancer patients ranges from 2.3%-45.2%. This study aimed to determine the risk factors for newly developed NAFLD among breast cancer patients after hormonal treatment and whether it influences survival outcomes.